NCT04676477: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
- State
- Under way
- Phase
- Phase 1
- People
- 246 taking part
- Started
- 11 Jun 2021
- Primary completion
- 31 Jan 2025
- Arms
- Dose Escalation: HER3-DXd + osimertinib, Second-line Dose Expansion: HER3-DXd + osimertinib (RCD), First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 3; RCD), First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 4a), First-line Dose Expansion: HER3-DXd + osimertinib (Cohort 4b)
- Results
- None posted
- 21 Dec 2020: Trial registered
- 11 Jun 2021: Trial started